Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Medicine & Life Sciences

• lixisenatide 100%
• Acute Coronary Syndrome 59%
• Type 2 Diabetes Mellitus 44%
• Placebos 40%
• Glucagon-Like Peptide-1 Receptor 15%
• Peptide Receptors 14%
• Morbidity 13%
• Safety 13%
• Unstable Angina 13%
• Mortality 11%
• Pancreatitis 11%
• Hypoglycemia 11%
• Multicenter Studies 10%
• Hospitalization 8%
• Myocardial Infarction 8%
• Cardiovascular Diseases 8%
• Body Mass Index 8%
• Stroke 8%
• Population 4%
• Neoplasms 3%